# Clinical Efficacy & Safety, of Metadoxine (MG01CI) Extended Release in Attention-Deficit Hyperactivity Disorder (ADHD)

> **NCT01243242** · PHASE2 · COMPLETED · sponsor: **Alcobra Ltd.** · enrollment: 120 (actual)

## Conditions studied

- ADHD

## Interventions

- **DRUG:** Metadoxine (MG01CI)

## Key facts

- **NCT ID:** NCT01243242
- **Lead sponsor:** Alcobra Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2011-08
- **Final completion:** 2011-09
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2012-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01243242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01243242, "Clinical Efficacy & Safety, of Metadoxine (MG01CI) Extended Release in Attention-Deficit Hyperactivity Disorder (ADHD)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01243242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*